Enveric Biosciences (NASDAQ:ENVB – Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($3.45) per share for the quarter.
Enveric Biosciences Stock Down 3.5 %
NASDAQ:ENVB traded down $0.05 during midday trading on Tuesday, reaching $1.25. The stock had a trading volume of 5,583 shares, compared to its average volume of 731,671. The stock has a market cap of $3.08 million, a P/E ratio of -0.03 and a beta of 0.68. Enveric Biosciences has a 12-month low of $1.01 and a 12-month high of $15.45. The firm has a fifty day simple moving average of $1.51 and a two-hundred day simple moving average of $3.72.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Enveric Biosciences in a research report on Thursday, March 6th.
About Enveric Biosciences
Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
Read More
- Five stocks we like better than Enveric Biosciences
- What is the S&P/TSX Index?
- Palantir Stock Drops Despite Stellar Earnings: What’s Next?
- What Makes a Stock a Good Dividend Stock?
- D-Wave Quantum: Hidden Opportunity or Short Seller’s Dream?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Uncertainty Creates Opportunity for Tyson Foods Investors
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
